XIGDUO XR 5/1000 dapagliflozin 5 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xigduo xr 5/1000 dapagliflozin 5 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack

astrazeneca pty ltd - dapagliflozin propanediol monohydrate, quantity: 6.15 mg (equivalent: dapagliflozin, qty 5 mg); metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: carmellose sodium; lactose; hypromellose; silicon dioxide; crospovidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

XIGDUO XR 10/1000 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xigduo xr 10/1000 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack

astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg) - tablet, modified release - excipient ingredients: crospovidone; lactose; hypromellose; magnesium stearate; carmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

XIGDUO XR 10/500 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 500 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xigduo xr 10/500 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 500 mg modified release tablets blister pack

astrazeneca pty ltd - metformin hydrochloride, quantity: 500 mg; dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; lactose; silicon dioxide; hypromellose; crospovidone; carmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

Dapagliflozin Krka 10 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

dapagliflozin krka 10 mg film-coated tablets

krka, d.d., novo mesto - dapagliflozin - film-coated tablet - dapagliflozin

Dapagliflozin Krka 5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

dapagliflozin krka 5 mg film-coated tablets

krka, d.d., novo mesto - dapagliflozin - film-coated tablet - dapagliflozin

FORXIGA TABLET Canada - English - Health Canada

forxiga tablet

astrazeneca canada inc - dapagliflozin (dapagliflozin propanediol monohydrate) - tablet - 5mg - dapagliflozin (dapagliflozin propanediol monohydrate) 5mg - sodium-glucose cotransporter 2 (sglt2) inhibitors

FORXIGA TABLET Canada - English - Health Canada

forxiga tablet

astrazeneca canada inc - dapagliflozin (dapagliflozin propanediol monohydrate) - tablet - 10mg - dapagliflozin (dapagliflozin propanediol monohydrate) 10mg - sodium-glucose cotransporter 2 (sglt2) inhibitors

XIGDUO TABLET Canada - English - Health Canada

xigduo tablet

astrazeneca canada inc - dapagliflozin (dapagliflozin propanediol monohydrate); metformin hydrochloride - tablet - 5mg; 850mg - dapagliflozin (dapagliflozin propanediol monohydrate) 5mg; metformin hydrochloride 850mg - biguanides

XIGDUO TABLET Canada - English - Health Canada

xigduo tablet

astrazeneca canada inc - dapagliflozin (dapagliflozin propanediol monohydrate); metformin hydrochloride - tablet - 5mg; 1000mg - dapagliflozin (dapagliflozin propanediol monohydrate) 5mg; metformin hydrochloride 1000mg - biguanides

DAPAMET XR 5MG/500MG TABLETS Kenya - English - Pharmacy and Poisons Board

dapamet xr 5mg/500mg tablets

m/s. innocia lifesciences pvt. ltd. block a, no.12, balaji nagar, ambattur, chennai – - dapagliflozin propanediol monohydrate & metformin… - tablet - dapagliflozin propanediol monohydrate equivalent… - metformin and dapagliflozin